Opus Genetics
IRD
17 hedge funds and large institutions have $470K invested in Opus Genetics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
7,161% more capital inflows, than outflows
Capital inflows: $78.1K | Capital outflows: $1.08K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 16 → 17 (+1)
1.01% more ownership
Funds ownership: 5.15% → 6.16% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$73.9K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.82K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.33K |
| 4 |
Squar Milner Financial Services
Irvine,
California
|
+$30 |
| 5 |
TCI Wealth Advisors
Tucson,
Arizona
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
| 2 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$53 |
| 3 |
Morgan Stanley
New York
|
-$23 |
IRD Hedge Fund Activity: Q4 2019 in Review
17 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2019, worth a combined $470K — up 11% from $422K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IRD positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $73.9K. The largest seller was Victory Capital Management, exiting entirely with an estimated $1K sold.
- 17 institutional investors held Opus Genetics (IRD) as of Q4 2019, up from 16 in Q3 2019.
- Funds reported $470K of Opus Genetics stock for Q4 2019, up 11% quarter-over-quarter.
- 4 funds opened new Opus Genetics positions in Q4 2019 and 3 closed out, a net change of +1 holder.
- The largest Opus Genetics buyer in Q4 2019 was Renaissance Technologies, an estimated $73.9K added.
- The largest Opus Genetics seller in Q4 2019 was Victory Capital Management, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2019.